Format
Sort by
Items per page

Send to

Choose Destination

Best matches for galectin-3 AND kidney OR galectin-3 AND renal:

Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander. Desmedt V et al. Am J Nephrol. (2016)

The Role of Galectin-3 in the Kidneys. Chen SC et al. Int J Mol Sci. (2016)

Galectin-3 and prediction of therapeutic response to renal sympathetic denervation. Schwerg M et al. Clin Exp Hypertens. (2016)

Search results

Items: 1 to 20 of 219

1.

Macrophages restrict the nephrogenic field and promote endothelial connections during kidney development.

Munro DA, Wineberg Y, Tarnick J, Vink CS, Li Z, Pridans C, Dzierzak E, Kalisky T, Hohenstein P, Davies JA.

Elife. 2019 Feb 13;8. pii: e43271. doi: 10.7554/eLife.43271.

2.

Soluble ST2 and Galectin-3 and Progression of CKD.

Alam ML, Katz R, Bellovich KA, Bhat ZY, Brosius FC, de Boer IH, Gadegbeku CA, Gipson DS, Hawkins JJ, Himmelfarb J, Kestenbaum BR, Kretzler M, Robinson-Cohen C, Steigerwalt SP, Tuegel C, Bansal N.

Kidney Int Rep. 2018 Sep 21;4(1):103-111. doi: 10.1016/j.ekir.2018.09.013. eCollection 2019 Jan.

3.

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes.

Ghorbani A, Bhambhani V, Christenson RH, Meijers WC, deBoer RA, Levy D, Larson MG, Ho JE.

J Am Coll Cardiol. 2018 Dec 25;72(25):3246-3254. doi: 10.1016/j.jacc.2018.09.076.

PMID:
30573026
4.

Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction.

Yogasundaram H, Nikhanj A, Putko BN, Boutin M, Jain-Ghai S, Khan A, Auray-Blais C, West ML, Oudit GY.

J Am Heart Assoc. 2018 Nov 6;7(21):e009098. doi: 10.1161/JAHA.118.009098.

5.

The association among biomarkers of renal and heart function in patients with heart failure: the role of NGAL.

Oikonomou E, Tsalamandris S, Karlis D, Siasos G, Chrysohoou C, Vogiatzi G, Dimitropoulos S, Charalambous G, Kouskouni E, Tousoulis D.

Biomark Med. 2018 Dec 4. doi: 10.2217/bmm-2018-0100. [Epub ahead of print]

PMID:
30511581
6.

Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity.

Li HY, Yang S, Li JC, Feng JX.

Biosci Rep. 2018 Dec 18;38(6). pii: BSR20181803. doi: 10.1042/BSR20181803. Print 2018 Dec 21.

PMID:
30455396
7.

Galectin-3 Interacts with Vascular Cell Adhesion Molecule-1 to Increase Cardiovascular Mortality in Hemodialysis Patients.

Ko WC, Choy CS, Lin WN, Chang SW, Liou JC, Tung TH, Hsieh CY, Chang JF.

J Clin Med. 2018 Sep 24;7(10). pii: E300. doi: 10.3390/jcm7100300.

8.

Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma.

Huang CS, Tang SJ, Lee MH, Chang Wang CC, Sun GH, Sun KH.

J Cell Mol Med. 2018 Dec;22(12):5909-5918. doi: 10.1111/jcmm.13860. Epub 2018 Sep 24.

9.

Vps34/PI3KC3 deletion in kidney proximal tubules impairs apical trafficking and blocks autophagic flux, causing a Fanconi-like syndrome and renal insufficiency.

Grieco G, Janssens V, Gaide Chevronnay HP, N'Kuli F, Van Der Smissen P, Wang T, Shan J, Vainio S, Bilanges B, Jouret F, Vanhaesebroeck B, Pierreux CE, Courtoy PJ.

Sci Rep. 2018 Sep 20;8(1):14133. doi: 10.1038/s41598-018-32389-z.

10.

Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome.

Melenovsky V, Cervenka L, Viklicky O, Franekova J, Havlenova T, Behounek M, Chmel M, Petrak J.

Kidney Blood Press Res. 2018;43(5):1437-1450. doi: 10.1159/000493657. Epub 2018 Sep 20.

11.

BIOMARKERS OF RENAL INJURY RISK IN CHILDREN WITH PYELONEPHRITIS.

Sorokman T, Sokolnyk S, Popelyuk O, Makarova O, Kopchuk T.

Georgian Med News. 2018 Jul-Aug;(280-281):98-103.

PMID:
30204104
12.

Role of Response-to-Diuretic in Predicting Prognosis in Discharged Heart Failure Patients After an Acute Decompensation.

Feola M, Testa M, Ferreri C, Cardone M, Sola M, Ariotti S, Rosso GL.

Arch Med Res. 2018 Apr;49(3):198-204. doi: 10.1016/j.arcmed.2018.08.007. Epub 2018 Aug 14. Erratum in: Arch Med Res. 2018 Dec 13;:.

PMID:
30119980
13.

Expression of galectin-1 and galectin-3 in renal cell carcinoma; immunohistochemical study.

Aboulhagag NA, El-Deek HEM, Sherif MF.

Ann Diagn Pathol. 2018 Oct;36:31-37. doi: 10.1016/j.anndiagpath.2018.06.005. Epub 2018 Jun 21.

PMID:
30055522
14.

Non-natriuretic peptide biomarkers in heart failure with preserved and reduced ejection fraction.

Oikonomou E, Vogiatzi G, Tsalamandris S, Mourouzis K, Siasos G, Lazaros G, Skotsimara G, Marinos G, Vavuranakis M, Tousoulis D.

Biomark Med. 2018 Jul;12(7):783-797. doi: 10.2217/bmm-2017-0376. Epub 2018 Jun 5.

PMID:
29865857
15.

Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure.

Nguyen MN, Su Y, Vizi D, Fang L, Ellims AH, Zhao WB, Kiriazis H, Gao XM, Sadoshima J, Taylor AJ, McMullen JR, Dart AM, Kaye DM, Du XJ.

Sci Rep. 2018 May 29;8(1):8213. doi: 10.1038/s41598-018-26115-y.

16.

Galectin-3 deficiency drives lupus-like disease by promoting spontaneous germinal centers formation via IFN-γ.

Beccaria CG, Amezcua Vesely MC, Fiocca Vernengo F, Gehrau RC, Ramello MC, Tosello Boari J, Gorosito Serrán M, Mucci J, Piaggio E, Campetella O, Acosta Rodríguez EV, Montes CL, Gruppi A.

Nat Commun. 2018 Apr 24;9(1):1628. doi: 10.1038/s41467-018-04063-5.

17.

Association of Pentraxin-3, Galectin-3 and Matrix Metalloproteinase-9/Timp-1 with Cardiovascular Risk in Renal Disease Patients.

Miljković M, Stefanović A, Bogavac-Stanojević N, Simić-Ogrizović S, Dumić J, Černe D, Jelić-Ivanović Z, Kotur-Stevuljević J.

Acta Clin Croat. 2017 Dec;56(4):673-680. doi: 10.20471/acc.2017.56.04.14.

PMID:
29590722
18.

Identification of targets of IL-13 and STAT6 signaling in polycystic kidney disease.

Olsan EE, West JD, Torres JA, Doerr N, Weimbs T.

Am J Physiol Renal Physiol. 2018 Jul 1;315(1):F86-F96. doi: 10.1152/ajprenal.00346.2017. Epub 2018 Mar 7.

PMID:
29513071
19.

Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus.

Tan KCB, Cheung CL, Lee ACH, Lam JKY, Wong Y, Shiu SWM.

Diabetologia. 2018 May;61(5):1212-1219. doi: 10.1007/s00125-018-4552-z. Epub 2018 Feb 7.

PMID:
29417184
20.

Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.

Suthahar N, Meijers WC, Silljé HHW, Ho JE, Liu FT, de Boer RA.

Theranostics. 2018 Jan 1;8(3):593-609. doi: 10.7150/thno.22196. eCollection 2018. Review.

Supplemental Content

Loading ...
Support Center